TETANUS AND DIPHTHERIA TOXOIDS ADSORBED Rx
Generic Name and Formulations:
Tetanus and diphtheria toxoids; aluminum adsorbed; susp for IM inj; contains residual formaldehyde, thimerosal (trace); latex-free.
Merck & Co., Inc.
Indications for TETANUS AND DIPHTHERIA TOXOIDS ADSORBED:
Tetanus and diphtheria immunization in patients ≥7yrs.
Adults and Children:
<7yrs: not recommended. ≥7yrs: Give IM in deltoid muscle. Previously unvaccinated: three 0.5mL doses at elected date, then 4–8 weeks after first dose, and 6–12 months after second dose. Give booster dose at 11–12yrs of age if last dose of tetanus and diphtheria toxoid-containing vaccine was given ≥5yrs ago. Other: give booster every 10yrs. Diphtheria and tetanus prophylaxis: see full labeling.
Anaphylaxis associated with a previous dose.
Guillain-Barre syndrome within 6 weeks of previous tetanus toxoid vaccine. Previous Arthus-type hypersensitivity reaction: not recommended until ≥10yrs after prior dose of tetanus toxoid-containing vaccine. Immunodeficiency. Have epinephrine (1:1000) available. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant vaccines: see full labeling. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Local reactions (eg, erythema, tenderness), dizziness, headache, myalgia, fever; rare: neurological disorders.
Formerly known under the brand name Decavac.
Single-dose vials (0.5mL)—10
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a